國立虎尾科技大學 |

Analogue-based drug discovery III

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Analogue-based drug discovery III/ edited by János Fischer, C. Robin Ganellin, David P. Rotella.
其他題名:	Analogue-based drug discovery 3
其他作者:	Fischer, János.
出版者:	Weinheim :Wiley-VCH, : c2013.,
面頁冊數:	1 online resource.
標題:	Drug development. -
電子資源:	http://onlinelibrary.wiley.com/book/10.1002/9783527651085
ISBN:	9783527651085 (electronic bk.)

Analogue-based drug discovery III
Analogue-based drug discovery III[electronic resource] /Analogue-based drug discovery 3edited by János Fischer, C. Robin Ganellin, David P. Rotella. - Weinheim :Wiley-VCH,c2013. - 1 online resource.

Includes bibliographical references and index.

General Aspects. Pioneer and Analogue Drugs / Janos Fischer, C Robin Ganellin, David P Rotella -- Competition in the Pharmaceutical Drug Development / Christian Tyrchan, Fabrizio Giordanetto -- Metabolic Stability and Analogue-Based Drug Discovery / Amit S Kalgutkar, Antonia F Stepan -- Use of Macrocycles in Drug Design Exemplified with Ulimorelin, a Potential Ghrelin Agonist for Gastrointestinal Motility Disorders / Mark L Peterson, Hamid Hoveyda, Graeme Fraser, Eric Marsault, Rene Gagnon -- Drug Classes. The Discovery of Anticancer Drugs Targeting Epigenetic Enzymes / A Ganesan -- Thienopyridyl and Direct-Acting P2Y Receptor Antagonist Antiplatelet Drugs / Joseph A Jakubowski, Atsuhiro Sugidachi -- Selective Estrogen Receptor Modulators / Amarjit Luniwal, Rachael Jetson, Paul Erhardt -- Discovery of Nonpeptide Vasopressin V2 Receptor Antagonists / Kazumi Kondo, Hidenori Ogawa -- The Development of Cysteinyl Leukotriene Receptor Antagonists / Peter R Bernstein -- Case Studies. The Discovery of Dabigatran Etexilate / Norbert Hauel, Andreas Clemens, Herbert Nar, Henning Priepke, Joanne van Ryn, Wolfgang Wienen -- The Discovery of Citalopram and Its Refinement to Escitalopram / Klaus P Bogeso, Connie Sanchez -- Tapentadol : From Morphine and Tramadol to the Discovery of Tapentadol / Helmut Buschmann -- Novel Taxanes: Cabazitaxel Case Study / Herve Bouchard, Dorothee Semiond, Marie-Laure Risse, Patricia Vrignaud -- Discovery of Boceprevir and Narlaprevir: A Case Study for Role of Structure-Based Drug Design / Srikanth Venkatraman, Andrew Prongay, George F Njoroge -- A New-Generation Uric Acid Production Inhibitor: Febuxostat / Ken Okamoto, Shiro Kondo, Takeshi Nishino.

Most drugs are analogue drugs. There are no general rules how a new drug can be discovered, nevertheless, there are some observations which help to find a new drug, and also an individual story of a drug discovery can initiate and help new discoveries. Volume III is a continuation of the successful book series with new examples of established and recently introduced drugs. The major part of the book is written by key inventors either as a case study or a study of an analogue class. With its wide range across a variety of therapeutic fields and chemical classes, this is of interest to virtu

ISBN: 9783527651085 (electronic bk.)Subjects--Topical Terms:

581824
Drug development.

LC Class. No.: RM301.25 / .A53 2013

Dewey Class. No.: 615.1/9

Analogue-based drug discovery III
LDR:03480cam a2200337Ka 4500 001 795320
003 OCoLC
005 20130505100552.0
006 m o d
007 cr |||||||||||
008 150505s2013 gw ob 001 0 eng d
020 $a 9783527651085 (electronic bk.)
020 $a 352765108X (electronic bk.)
020 $a 9783527651115 (electronic bk.)
020 $a 352765111X (electronic bk.)
020 $z 9783527330737
020 $z 3527330739
020 $a 9781299241206 (MyiLibrary)
020 $a 1299241204 (MyiLibrary)
035 $a 005417635
040 $a DG1 $c DG1 $d EBLCP $d N $d MHW $d YDXCP $d COO
050 4 $a RM301.25 $b .A53 2013
082 0 4 $a 615.1/9 $2 23
245 0 0 $a Analogue-based drug discovery III $h [electronic resource] / $c edited by János Fischer, C. Robin Ganellin, David P. Rotella.
246 3 $a Analogue-based drug discovery 3
260 $a Weinheim : $b Wiley-VCH, $c c2013.
300 $a 1 online resource.
504 $a Includes bibliographical references and index.
505 0 $a General Aspects. Pioneer and Analogue Drugs / Janos Fischer, C Robin Ganellin, David P Rotella -- Competition in the Pharmaceutical Drug Development / Christian Tyrchan, Fabrizio Giordanetto -- Metabolic Stability and Analogue-Based Drug Discovery / Amit S Kalgutkar, Antonia F Stepan -- Use of Macrocycles in Drug Design Exemplified with Ulimorelin, a Potential Ghrelin Agonist for Gastrointestinal Motility Disorders / Mark L Peterson, Hamid Hoveyda, Graeme Fraser, Eric Marsault, Rene Gagnon -- Drug Classes. The Discovery of Anticancer Drugs Targeting Epigenetic Enzymes / A Ganesan -- Thienopyridyl and Direct-Acting P2Y Receptor Antagonist Antiplatelet Drugs / Joseph A Jakubowski, Atsuhiro Sugidachi -- Selective Estrogen Receptor Modulators / Amarjit Luniwal, Rachael Jetson, Paul Erhardt -- Discovery of Nonpeptide Vasopressin V2 Receptor Antagonists / Kazumi Kondo, Hidenori Ogawa -- The Development of Cysteinyl Leukotriene Receptor Antagonists / Peter R Bernstein -- Case Studies. The Discovery of Dabigatran Etexilate / Norbert Hauel, Andreas Clemens, Herbert Nar, Henning Priepke, Joanne van Ryn, Wolfgang Wienen -- The Discovery of Citalopram and Its Refinement to Escitalopram / Klaus P Bogeso, Connie Sanchez -- Tapentadol : From Morphine and Tramadol to the Discovery of Tapentadol / Helmut Buschmann -- Novel Taxanes: Cabazitaxel Case Study / Herve Bouchard, Dorothee Semiond, Marie-Laure Risse, Patricia Vrignaud -- Discovery of Boceprevir and Narlaprevir: A Case Study for Role of Structure-Based Drug Design / Srikanth Venkatraman, Andrew Prongay, George F Njoroge -- A New-Generation Uric Acid Production Inhibitor: Febuxostat / Ken Okamoto, Shiro Kondo, Takeshi Nishino.
520 $a Most drugs are analogue drugs. There are no general rules how a new drug can be discovered, nevertheless, there are some observations which help to find a new drug, and also an individual story of a drug discovery can initiate and help new discoveries. Volume III is a continuation of the successful book series with new examples of established and recently introduced drugs. The major part of the book is written by key inventors either as a case study or a study of an analogue class. With its wide range across a variety of therapeutic fields and chemical classes, this is of interest to virtu
588 $a Description based on title page from PDF version; (Wiley Online Library; viewed on Feb. 4, 2013).
650 0 $a Drug development. $3 581824
700 1 $a Fischer, János. $3 999819
700 1 $a Ganellin, C. R. $q (C. Robin) $3 965986
700 1 $a Rotella, David P. $3 999820
856 4 0 $u http://onlinelibrary.wiley.com/book/10.1002/9783527651085